Laronidase (Aldurazyme)

Covered only for FDA‑approved MPS I indications (Hurler, Hurler‑Scheie, and Scheie with moderate‑to‑severe symptoms); all other uses are excluded. Key requirements: diagnostic confirmation by deficient α‑L‑iduronidase enzyme assay or pathogenic IDUA gene mutation, prescribed by or in consultation with a geneticist/endocrinologist/metabolic or lysosomal storage disorder specialist, dosing ≤0.58 mg/kg IV no more than once weekly, and authorization granted for up to 12 months with documentation of MPS I subtype and symptom severity.

"Aldurazyme (laronidase) is indicated for the treatment of individuals with the Hurler or Hurler-Scheie forms of mucopolysaccharidosis type I."

Sign up to see full coverage criteria, indications, and limitations.